One Lambda CXCL10 Testing Services

Noninvasive urine-based biomarker that can support routine testing for graft dysfunction

This test detects the CXCL10 chemokine in human urine samples and multiple clinical studies have shown that elevated CXCL10 is associated with inflammation and early graft dysfunction. Current testing methods can be invasive, can lack specificity, and may produce results too late to influence care. 



CXCL10 testing key features and benefits

  • Noninvasive: A painless urine-based test that may be collected same day in clinic1
  • Fast reporting: Results available in as little as 24 hours*, which can provide clinicians with valuable information faster than currently used tests2,3
  • Less expensive: Lower cost than other available biomarkers, which can support more frequent monitoring4,5
  • Highly specific: Studies have demonstrated that molecular tests can be reliably used to assess allograft dysfunction2,6,7,8

Thermo Fisher Scientific One Lambda Laboratory Services


Our new Thermo Fisher Scientific clinical laboratory delivers advanced testing services to clinicians, offering precise analysis of genetic markers and biomarkers that provide information on organ health. For patients, our cutting-edge tests provide personalized information that support the long-term success of organ transplants.

Supplementing current standards of care

CXCL10 testing services provide information that supplements current standards of care which may:

  • Lack specificity or sensitivity, which can make them unreliable to rule out rejection or injury, and may lead to unnecessary biopsies9
  • Produce results too late to influence care by identifying rejection risk later, which makes treating rejection more difficult and can lead to aggressive immunosuppression regime, resulting in increased morbidity and mortality risks9
  • Include invasive testing, which can be painful for patients and time-consuming for clinicians10
  • Be expensive, which can reduce the frequency of monitoring and lead to delayed treatment11

Personalized consultative service and support

  • Seamless service enabling our customers to deliver more personalized, responsive care that can improve outcomes
  • Support for system access, result interpretation, and administrative questions
  • We provide administrative support through service implementation to help enable a successful experience

Learn more about One Lambda CXCL10 testing services

* Results are available in as little as 24 hours after sample receipt.

1. Arnau A, Benito-Hernández A, Ramos-Barrón MA, et al. Urinary C-X-C Motif Chemokine 10 Is Related to Acute Graft Lesions Secondary to T Cell- and Antibody-Mediated Damage. Ann Transplant. 2021;26:e929491.

2. Ho J, Sharma A, Mandal R, et al. Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. Transplant Direct. 2016;2(6):e78.

3. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 2006;69(9):1683-1690.

4. Puttarajappa CM, Mehta RB, Roberts MS, Smith KJ, Hariharan S. Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers. Am J Transplant. 2021;21(1):186-197.

5. Ho J, Sharma A, Kroeker K, et al. Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. BMJ Open. 2019;9(4):e024908.

6. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation. 2005;79(9):1215-1220.

7. Ho J, Schaub S, Wiebe C, et al. Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation. Transplantation. 2018;102(3):521-529.

8. Başak Oktay S, Akbaş SH, Yilmaz VT, Özen Küçükçetin İ, Toru HS, Yücel SG. Association Between Graft Function and Urine CXCL10 and Acylcarnitines Levels in Kidney Transplant Recipients. Lab Med. 2022;53(1):78-84.

9. Chen T, Wang Y, Tian D, et al. Follow-Up Factors Contribute to Immunosuppressant Adherence in Kidney Transplant Recipients. Patient Prefer Adherence. 2022;16:2811-2819.

10. Baker RJ, Mark PB, Patel RK, Stevens KK, Palmer N. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol. 2017;18(1):174.

11. Swanson KJ, Aziz F, Garg N, et al. Role of novel biomarkers in kidney transplantation. World J Transplant. 2020;10(9):230-255.

 

The One Lambda Laboratories CXCL10 assay was developed and validated by One Lambda Laboratories. This laboratory developed test (LDT) is used for clinical purposes by the CLIA-certified laboratory performing the test. This test has not been cleared or approved by the FDA as an in vitro diagnostic test.